top of page
Home: Welcome
Precision NK therapies have the potential to revolutionize cancer treatment with unsurpassed safety and efficacy. We are excited to bring NK Cell Engager antibodies and CAR-NK cell therapies to initial clinical trials starting in 2022, moving towards broad patient access to cancer-defeating cures."
Dr. Daniel Teper,
Cytovia Therapeutics CEO
Cytovia In The News
October 12th, 2021
bottom of page